Sirona Biochem Corp. announced the achievement of the first batch of compound in the joint venture with Bloom Burton & Co. Compounds developed within the framework of the joint venture (JV) will be entering development in the areas of rare inflammatory and infectious diseases.

 

At present, there are unmet market needs in the areas of rare or neglected inflammatory diseases and bacterial resistance. Sirona and Bloom Burton are identifying and designing a library of compounds to address these substantial markets which combined reach nearly $2 Billion US each year globally. Sirona is responsible for the chemistry and Bloom Burton for the financing, clinical validation as well as the commercialization of the compounds. 

 

“We could not be more pleased with the completion of the first synthetic compounds. This is a major milestone in the development of our portfolio for rare and neglected diseases,” said Howard Verrico, CEO of Sirona Biochem. “The team at Bloom Burton will plan for the testing of our new anti-inflammatory compounds in the near future. In the next several months, we will be working on the development of further compounds for our JV with Bloom Burton as planned.”

 

Date: July 31, 2014

Source: Sirona Biochem